id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-350466-z5yvfo22	Jena, Anuraag	Fecal calprotectin levels in COVID-19: Lessons from a systematic review on its use in inflammatory bowel disease during the pandemic	2020-10-19		.txt	text/plain	772	57	50	title: Fecal calprotectin levels in COVID-19: Lessons from a systematic review on its use in inflammatory bowel disease during the pandemic 8 We therefore performed a systematic review to study the elevations of fecal calprotectin in COVID-19 and if these elevations were different in patients with or without gastrointestinal symptoms . After removing the duplicates, we screened for the original studies reporting about fecal calprotectin in COVID-19 patients. These four studies reported about fecal calprotectin levels in 174 patients with COVID-19 ( Table 1) . The elevations of fecal calprotectin were more frequent in those patients who had gastrointestinal symptoms in all the three studies which provided this information (Figure 1 ). Further, as patients of IBD with elevated fecal calprotectin levels could be immunocompromised, it would be better to exclude COVID-19 infection prior to increasing immunosuppression. Also, there are no direct studies of fecal calprotectin in IBD patients infected with COVID-19.	./cache/cord-350466-z5yvfo22.txt	./txt/cord-350466-z5yvfo22.txt